Participants
Study participants included 15 young healthy men aged 22 ± 1.5 years. The study inclusion criteria included voluntary written consent, absence of medical contraindications, no history of infections, and no injuries in the last 4 weeks prior to the study. Exclusion criteria including the intake of antibiotics, steroids, oral antifungal agents (except for topical antifungals), antiparasitic agents, pre- and/or probiotics, history of travel to tropical countries during the last 4 weeks before the study, and history of adverse responses to sauna bathing.
Procedure
This study utilized a randomized, parallel group design. The participants were randomly assigned to exercise training (ET) with or without post-exercise sauna treatments (S). Participants in the group ET + S (n = 8) exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry sauna treatment. The control group (ET, n = 7) engaged in the same exercise training program without the sauna treatments. The 60-minute exercise bouts were performed on calibrated Keiser M3 ergometers (Germany). The initial exercise intensity was set at 50% VO2peak for 2 weeks, and then increased to 60% for the final two weeks of training. The physical exercise was performed in controlled environmental conditions (temperature of 22–23°C, and relative humidity of 30–33%) with no use of fans or cold drinks. Immediately after finishing the 60-minute exercise bout, subjects from group ET + S spent 30 minutes in a dry sauna (in the sitting position), at a temperature of approximately 90°C at the chest level and relative humidity of air 10 ± 2%. The sauna treatment was divided into two or three parts (e.g. 3 x 10 minutes, 2 x 15 minutes), and subjects were allowed to cool the body for a maximum of 3-min (e.g. by taking a cold shower, immersing the body in cool water up to the armpits).
Participants agreed to maintain normal dietary intake patterns, and this was verified with 3-day food records at the beginning and end of the 4-week study. Energy and nutrient intake was calculated using the NUVERO application.
Blood and stool sample collection
Blood and stool samples were collected before and after the 4-week study. Blood samples (approx. 2 ml) were taken from the antecubital vein and centrifuged at 4000 rpm and 4°C. The serum was separated from the sample and stored at − 70°C. The concentration of high-sensitivity C-reactive protein (hsCRP) was measured by immunoenzymatic assay using a commercially available kit (DRG International Inc., Springfield Township, NJ, USA; test sensitivity: 0.1 mg/L and 5 ng/mL). Complete blood count indices were determined by flow cytometry with a Synergy 2 SIAFRT analyser (Bio Tek, Winooski, VT, USA).
In order to perform qualitative analyses of selected indicator bacteria in the gastrointestinal tract, and to determine the stool pH, the studied men were requested to provide a stool sample within 24 hours of collection. Stool sample collection was performed according to the established protocol developed by KyberKompaktPRO (Institute of Microecology). To this end, a 150-ml sterile container was to be filled to three quarters of its volume with material preferably taken from eight different locations, and closed tightly with a lid. The indicator bacteria, sIgA (marker of mucosal immunity), and the concentrations of zonulin (marker of intestinal permeability) in stool were evaluated before and after completing the training programme in both studied groups of men.
Bacterial DNA was isolated from stool samples using the QIAamp Fast DNA Stool Mini Kit (QIAGEN, Danish). An appropriate quantity of stool was weighed into a sterile tube. The isolation of bacterial DNA from the stool sample was performed according to the manufacturer's protocol. The DNA eluates were stored frozen until subsequent analyses.
The anaerobic bacteria including Faecalibacterium prausnitzi of the genus Faecalibacterium, Akkermansia muciniphila of the genus Akkermansia, Bifidobacterium spp. of the genus Actinobacteria, and Bacteroides spp. of the genus Bacteroidetes were determined by Real-Time PCR with appropriate primers (ThermoFisher Scientific, USA) (Table 2). The reaction mixture contained QuantiFast SYBR Green PCR Kit (Qiagen), RNase-free water (Qiagen), and a mixture of forward and reverse primers selected for the bacteria tested. The analyses were conducted in an ABI 7300 analyser (ThermoFisher Scientific, USA).
Bacterial DNA was isolated from a stool sample using the QIAamp Fast DNA Stool Mini Kit (QIAGEN). To this end, an appropriate quantity of stool was weighed into a sterile tube. The isolation of bacterial DNA from a stool sample was performed according to the manufacturer's protocol. The DNA eluates were stored frozen until subsequent analyses. The counts of anaerobic bacteria including Faecalibacterium prausnitzi of the genus Faecalibacterium, Akkermansia muciniphila of the genus Akkermansia, Bifidobacterium spp. of the genus Actinobacteria, and Bacteroides spp. of the genus Bacteroidetes were determined by Real-Time PCR with appropriate primers (ThermoFisher Scientific) listed in Table 1. The analyses were conducted in an ABI 7300 analyser (ThermoFisher Scientific).
Table 1
Standards applied for the determination of different microorganisms NS: non-significant difference
Name
|
Among
of DNA (copies/ml)
|
Product description
|
Bifidobacterium infantis DNA
|
5e8
|
Standard in identification of Bifidobacterium spp., isolated from Bifidobacterium infantis
|
Bacteroides fragilis DNA
|
2e9
|
Standard in identification of Bacteroides spp., isolated from Bacteroides fragilis
|
Faecalibacterium prausnitzii DNA
|
7,8e8
|
Standard in identification of Faecalibacterium prausnitzii
|
Akkermansia muciniphila DNA
|
3,9e8
|
Standard in identification of Akkermansia muciniphila
|
The final bacterial count/g of stool was obtained by converting the number of copies of the sequence amplified by PCR in the bacterial genome (for Faecalibacterium, Akkermansia muciniphila, Bifidobacterium spp., and Bacteroides spp., respectively) and the dilution factor applicable to the kit used for DNA isolation from stool samples. The conversion factor employed in the study was checked and validated at the Institute of Microecology in Herborn, Germany. Table 1 presents the standards used in the studies.
The limit of detection for the evaluated parameters was 102 [CFU/g of feces]. For values below 102 [CFU/g of feces] [cut-off point], the value of 0 was adopted for statistical analysis, which, however, does not mean that the test sample was bacteria-free. The results of quantitative bacterial analysis were converted to the decimal logarithm (Log10). The entire Real-Time PCR methodology was developed and validated by the Institute of Microecology in Herborn, Germany. Reference values for selected indicator bacteria and stool pH are presented in Table 2.
Table 2
Specific primers used for the determination of different microorganisms
Name
|
Product description
|
Sequence
|
Praus-F480
|
Faecalibacterium prausnitzii forward starter
|
CAGCAGCCGCGGTAAA
|
Praus-R631
|
Faecalibacterium prausnitzii reverse starter
|
CTACCTCTGCACTACTCAAGAAA
|
Akk.muc-F
|
Akkermansia muciniphila starter forward
|
CAGCACGTGAAGGTGGGGAC
|
Akk.muc-R
|
Akkermansia muciniphila starter reverse
|
CCTTGCGGTTGGCTTCAGAT
|
F-Bifid09c
|
Bifidobacterium spp. forward starter
|
CGGGTGAGTAATGCGTGACC
|
R-Bifid06
|
Bifidobacterium spp. reverse starter
|
TGATAGGACGCGACCCCA
|
Bacter11
|
Bacteroides spp. forward starter
|
CCTWCGATGGATAGGGGTT
|
Bacter08
|
Bacteroides spp. starter reverse
|
CACGCTACTTGGCTGGTTCAG
|
Uni-F340
|
Starter universal forward
|
ACTCCTACGGGAGGCAGCAGT
|
Uni-R514
|
Starter universal revers
|
ATTACCGCGGCTGCTGGC
|
The evaluation of stool zonulin and secretory immunoglobulin A (sIgA) concentrations required sample extraction. A stool extract was prepared using stool collection devices (Stool Sample Application System – SAS, K6998SAS) filled with 0.75 ml of washing buffer warmed to room temperature. Each stool sample was vortexed for homogeneity. In the next step, a stool collection device was inserted into the sample, so that all grooves in the device were filled with stool (15 mg), vortexed and analysed. Zonulin concentrations were assessed using the IKD Zonulin ELISA Kit (Immunodiagnostik AG, Bensheim, Germany). Secretory immunoglobulin A concentrations in stool samples were determined with the Secretory IgA test (ImmuChrom GmbH, Heppenheim, Germany). The minimum sensitivity of the test was 3.1 ng/ml.
The concentrations were measured by means of an immunoenzymatic method (ELISA) with a BioTek PowerWave XS spectrophotometer (USA).